4.4 Article

Performance of the modified Systemic Manifestation Score for systemic juvenile idiopathic arthritis in Adult-onset Still's disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Rheumatology

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

Piero Ruscitti et al.

Summary: This study compares the clinical features and treatments of systemic JIA and adult-onset Still's disease. The results reveal remarkable disparities in the prevalence of clinical manifestations between the two illnesses, which may partly depend on their classification by different criteria.

RHEUMATOLOGY (2022)

Article Rheumatology

Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?

Stephane Mitrovic et al.

Summary: A retrospective national survey revealed features of SpA in patients with SJIA/AOSD, with a prevalence of 6.58% in AOSD patients and 10% in SJIA patients. This suggests a possible overlap between SpA and AOSD that requires further study.

RHEUMATOLOGY (2022)

Article Rheumatology

Neutrophil-derived lipocalin-2 in adult-onset Still's disease: a novel biomarker of disease activity and liver damage

Jinchao Jia et al.

Summary: The study identified Lipocalin-2 (LCN2) as a potential biomarker for liver damage in adult-onset Still's disease (AOSD). LCN2 levels were found to be significantly elevated in AOSD patients compared to healthy controls, and were closely correlated with inflammatory markers and liver dysfunction. This suggests that LCN2 could be a useful tool for identifying AOSD patients with systemic inflammation, particularly those with liver involvement.

RHEUMATOLOGY (2021)

Article Rheumatology

Association of the Leukocyte Immunoglobulin-like Receptor A3 Gene With Neutrophil Activation and Disease Susceptibility in Adult-Onset Still's Disease

Mengyan Wang et al.

Summary: The study revealed that functional LILRA3 is a novel genetic risk factor for the development of AOSD and that functional LIR-A3 may play a pathogenic role by inducing formation of NETs.

ARTHRITIS & RHEUMATOLOGY (2021)

Article Medicine, General & Internal

Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still's Disease

Seoung Wan Nam et al.

Summary: This study evaluated the usefulness of serum interleukin (IL)-37 and IL-18 as disease activity markers of adult-onset Still's disease (AOSD) and found that they can complement each other in reflecting different aspects of AOSD. IL-37 correlated better with CRP while IL-18 correlated with ferritin, AST, and LDH, as well as certain disease manifestations like pleuritis and pneumonitis.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Immunology

Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults

Toshihiko Shiga et al.

Summary: The study suggests that IL-18 could be a useful biomarker for the differential diagnosis of AOSD and adult HLH. Serum IL-18 levels were significantly higher in the AOSD group compared to the adult HLH group, and were closely correlated with ferritin, soluble interleukin-2 receptor (sIL-2R), and other laboratory data.

FRONTIERS IN IMMUNOLOGY (2021)

Article Rheumatology

The implication of interferon-γ-producing immunocompetent cells for evaluating disease activity and severity in adult-onset Still's disease

Takanori Ichikawa et al.

Summary: The study found that increased serum levels of IFN-gamma, increased expression of IFN-gamma in CD4+ cells, and decreased NK cell proportion are associated with disease activity in AOSD. A lower proportion of NK cells may be useful for predicting a refractory clinical course in AOSD patients. Additionally, elevated serum levels of IL-6, IL-12, and IL-18 may persist after clinical remission in AOSD.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2021)

Article Rheumatology

Macrophage activation syndrome in a patient with adult-onset Still's disease following first COVID-19 vaccination with BNT162b2

Frederic Muench et al.

Summary: This case reports a 20-year-old female with AOSD who developed MAS six days after receiving her first COVID-19 vaccine dose of BNT162b2. The occurrence of MAS after vaccination is extremely rare, but in this particular case, the vaccination might have acted as a trigger for the development of MAS. Despite difficulties in establishing causality in rare adverse events, monitoring and reporting such complications are crucial, and do not diminish the overall benefit-risk ratio of licensed COVID-19 vaccines.

BMC RHEUMATOLOGY (2021)

Article Rheumatology

Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis

Benedetta Saccomanno et al.

JOURNAL OF RHEUMATOLOGY (2019)

Review Immunology

A comprehensive review on adult onset Still's disease

Roberto Giacomelli et al.

JOURNAL OF AUTOIMMUNITY (2018)

Review Rheumatology

Mechanisms, biomarkers and targets for adult-onset Still's disease

Eugen Feist et al.

NATURE REVIEWS RHEUMATOLOGY (2018)

Review Immunology

Adult-onset Still's disease

Mathieu Gerfaud-Valentin et al.

AUTOIMMUNITY REVIEWS (2014)